Navigating the Evolving Landscape of Atopic Dermatitis: Challenges and Future Opportunities: the 4th Davos Declaration

Claudia Traidl-Hoffmann¹, Jamie Afghani¹, Cezmi Akdis², Mubeccel Akdis³, Aydin Handan⁴, Katja Baerenfater⁵, Thomas Bieber², Paul L. Bigliardi⁶, Mei Bigliardi-Qi⁶, Charlotte Bonefeld⁷, Stefanie Bösch⁸, Marie-Charlotte Brüggen², Sebastian Diemert⁹, Hans-Werner Duchna², Martina Fähndrich¹⁰, Danielle Fehr², Marc Fellmann¹¹, Remo Frei², Lene Garvey⁷, Raschid Gharbo¹², Mehmet Gökken², Karin Grando², Carole Guillet⁸, Erman Güler¹³, Jan Gutermuth¹⁴, Nadine Herrmann¹⁵, DirkJan Hijnen¹⁶, Claudia Hülpüsch¹, Alan Irvine¹⁷, Erika Jensen-Jarolim¹⁸, Heidi H Kong¹⁹, Hillel Koren²⁰, Claudia Lang², Roger Lauener²¹, Laura Maintz¹⁵, Pierre-Yves Mantel², Emanuel maverakis²², Matthias Moehrensclager¹², Svenja Müller¹⁵, Kari Nadeau²³, Avidan U. Neumann¹, Liam O’Mahony²⁴, Fahafahantsoa Rapelanoro Rabenja²⁵, Harald Renz²⁶, Claudio Rhyner², Ernst Rietschel², Johannes Ring²⁷, Caroline Roduit²⁸, Mari Sasaki²⁹, Mirjam Schenk², Jens Schroder³⁰, Dagmar Simon³¹, Hans-Uwe Simon³², Milena Sokolowska², sonja stander³³, Martin Steinhoff³⁴, Doris Straub Piccirillo², Alain Taieb³⁵, Roberto Takaoka³⁶, Martin Tapparo³⁷, Henrik Teixeira⁴, Jacob Thyssen⁷, Stephan Traidl³⁸, Miriam Uhlmann², Willem van de Veen³, Marianne van Hage³⁹, Christian Virchow⁴⁰, Andreas Wollenberg⁴¹, Yasutaka mitamura³, Alexander Zink⁴², and Peter Schmid-Grendelmeier²

¹Universität Augsburg Medizinische Fakultät
²CK-CARE AG
³Universität Zurich Schweizerisches Institut fur Allergie- und Asthmaforschung
⁴AbbVie Inc
⁵Technische Universität München
⁶University of Minnesota Rochester
⁷University of Copenhagen
⁸University Hospital of Zürich
⁹Almirall Hermal GmbH
¹⁰LEO Pharmaceutical Products Sarath Ltd
¹¹Pfizer Switzerland AG
¹²Hochgebirgsklinik Davos AG
¹³Pfizer
¹⁴Universitätsklinikum Hamburg Eppendorf
¹⁵Universitätsklinikum Bonn Klinik und Poliklinik für Dermatologie und Allergologie
¹⁶Diakonessenhuis Utrecht Zeist Doorn Locatie Utrecht
¹⁷Trinity College Dublin
¹⁸Medizinische Universität Wien Zentrum für Pathophysiologie Infektiologie und Immunologie
¹⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health
Abstract

Aim: The 4th Davos Declaration, convened during the Global Allergy Forum (GAF) in Davos, aimed to elevate patient care for patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. Methods: This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. Results: The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. Conclusion: The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to work together to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.